As of 2026-05-13, the Relative Valuation of Recursion Pharmaceuticals Inc (RXRX) is (26.22) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.15 USD, the upside of Recursion Pharmaceuticals Inc based on Relative Valuation is -932.5%.
The range of the Relative Valuation is (25.50) - (24.96) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.9x - 23.0x | 22.6x |
| Forward P/E multiples | 20.2x - 20.4x | 20.3x |
| Fair Price | (25.50) - (24.96) | (26.22) |
| Upside | -909.6% - -892.5% | -932.5% |
| Date | P/E |
| 2026-05-12 | -2.58 |
| 2026-05-11 | -2.67 |
| 2026-05-08 | -2.72 |
| 2026-05-07 | -2.67 |
| 2026-05-06 | -2.81 |
| 2026-05-05 | -2.76 |
| 2026-05-04 | -2.88 |
| 2026-05-01 | -2.77 |
| 2026-04-30 | -2.83 |
| 2026-04-29 | -2.70 |
| 2026-04-28 | -2.79 |
| 2026-04-27 | -2.85 |
| 2026-04-24 | -2.87 |
| 2026-04-23 | -2.86 |
| 2026-04-22 | -3.05 |
| 2026-04-21 | -2.91 |
| 2026-04-20 | -3.02 |
| 2026-04-17 | -3.09 |
| 2026-04-16 | -2.94 |
| 2026-04-15 | -3.07 |
| 2026-04-14 | -2.90 |
| 2026-04-13 | -2.80 |
| 2026-04-10 | -2.68 |
| 2026-04-09 | -2.71 |
| 2026-04-08 | -2.77 |
| 2026-04-07 | -2.61 |
| 2026-04-06 | -2.58 |
| 2026-04-02 | -2.54 |
| 2026-04-01 | -2.50 |
| 2026-03-31 | -2.51 |
| 2026-03-30 | -2.32 |
| 2026-03-27 | -2.40 |
| 2026-03-26 | -2.58 |
| 2026-03-25 | -2.59 |
| 2026-03-24 | -2.59 |
| 2026-03-23 | -2.64 |
| 2026-03-20 | -2.66 |
| 2026-03-19 | -2.76 |
| 2026-03-18 | -2.72 |
| 2026-03-17 | -2.80 |
| 2026-03-16 | -2.77 |
| 2026-03-13 | -2.80 |
| 2026-03-12 | -2.69 |
| 2026-03-11 | -2.82 |
| 2026-03-10 | -2.81 |
| 2026-03-09 | -2.87 |
| 2026-03-06 | -2.83 |
| 2026-03-05 | -2.90 |
| 2026-03-04 | -2.98 |
| 2026-03-03 | -2.90 |